JeffreyERubnitzMD

Pediatric Hematology & Oncology • Memphis, TN

Director, Leukemia/Lymphoma Division, St. Jude Children's Research Hospital

Join to view full profile

Dr. Rubnitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rubnitz's full profile

Already have an account?

Office
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Pediatric Hematology/Oncology, 1991 - 1994
Stanford Health Care-Sponsored Stanford UniversityResidency, Pediatrics, 1988 - 1991
University of California San Diego School of MedicineClass of 1988

Certifications & Licensure

CA State Medical License 1989 - Present
TN State Medical License 1995 - 2026
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia Start of enrollment: 2002 Aug 01
Completed
Phase 3
Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia Start of enrollment: 2002 Mar 01
Completed
Phase 3
Natural Killer (NK) Cell Transplantation for AML Start of enrollment: 2005 Sep 01
Completed
Not Applicable
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2008 Aug 04
Completed
Phase 3
Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Start of enrollment: 2014 Aug 01
Completed
Phase 1
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2016 May 03
Terminated
Phase 1
Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia Start of enrollment: 2016 Jan 14
Terminated
Phase 2
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage Start of enrollment: 2017 Jul 11
Completed
Phase 1
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Start of enrollment: 2019 Feb 12
Active, not recruiting
Phase 1, Phase 2
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2017 Jun 15
Active, not recruiting
Phase 2
Roles: Contact, Principal Investigator
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy Start of enrollment: 2023 Feb 23
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Expanded Access Program for Revumenib
Available
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

417 citations
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
Jeffrey E. Rubnitz, Hiroto Inaba, Gary V. Dahl, Raul C. Ribeiro, W. Paul Bowman
The Lancet. Oncology. 2010-06-01
132 citations
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Vinod Pullarkat, Norman J. Lacayo, Elias Jabbour, Jeffrey E. Rubnitz, Ashish Bajel
Cancer Discovery. 2021-02-16
89 citations
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study.
Seth E. Karol, Thomas B. Alexander, Amit Budhraja, Stanley Pounds, Kristin Canavera
The Lancet. Oncology. 2020-03-11

Abstracts/Posters

Venetoclax in Combination with High-Dose Chemotherapy Is Active and Well-Tolerated in Children with Relapsed or Refractory Acute Myeloid LeukemiaClinically Relevant Ab...
Jeffrey Rubnitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Safety and Efficacy of Venetoclax in Combination with Navitoclax in Adult and Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Jeffrey Rubnitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A 5-Gene Ara-C, Daunorubicin and Etoposide (ADE) Drug Response Score As a Prognostic Tool to Predict AML Treatment Outcome
Jeffrey Rubnitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient ...
Jeffrey Rubnitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Integrative Analysis of Pediatric Acute Leukemia Identifies Immature Subtypes That Span a T Lineage and Myeloid Continuum with Distinct Prognoses
Jeffrey Rubnitz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Metabolomics Profiling Reveals Markers for Chemosensitivity and Clinical Outcomes in Pediatric AML Patients
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Using Pharmacogenomics to Guide Induction May Reduce Racial Disparities in Pediatric AMLDecember 9th, 2023
Drug Offers Promising Approach to Improve Outcome for Children with High-Risk LeukemiaFebruary 10th, 2016
Drug Offers Promising Approach to Improve Outcome for Children with High-Risk LeukemiaFebruary 10th, 2016
Join now to see all